Abstract
Objective: The aim of this work was to evaluate the association between pretreatment inflammation-based factors and outcomes in patients with macular edema (ME) secondary to retinal vein occlusion (RVO) and its subtypes after intravitreal ranibizumab or conbercept implant. Methods: This retrospective observational study included patients who were diagnosed with ME secondary to RVO at the First Affiliated Hospital of Nanchang University between January 2017 and January 2019, and who subsequently received intravitreal anti-vascular endothelial growth factor (VEGF) treatment. Blood-based parameters were measured before treatment, and correlations between best-corrected visual acuity (BCVA) and each of 3 parameters – neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) – were analyzed to identify predictors of effective intravitreal injection treatment outcomes. Results: A total of 315 treatment-naïve eyes treated with anti-VEGF drugs for RVO-ME were retrospectively analyzed in this study. The mean PLR value was significantly different in the effective and ineffective group for RVO-ME (138.03 ± 48.61 vs. 106.79 ± 27.28), branch RVO (BRVO)-ME (216.47 ± 53.04 vs. 185.94 ± 51.47), and central RVO (CRVO)-ME (231.07 ± 66.05 vs. 196.20 ± 60.44). The cutoff value of the PLR was 97.92, the area under the curve was 0.70, and the sensitivity and specificity were 81.5 and 44.3%, respectively. The mean NLR value was significantly different in the effective and ineffective groups for RVO-ME (2.20 ± 1.40 vs. 1.92 ± 0.89), and BRVO-ME (2.01 ± 0.80 vs. 1.82 ± 0.84), but not in patients with CRVO-ME (2.51 ± 2.02 vs. 2.12 ± 0.95). There are no significant differences between BRVO-ME and its subtype groups in MLR values. But the mean MLR value was significantly higher in the conbercept group than in the ranibizu-mab group among patients in the effective group (0.27 ± 0.11 vs. 0.25 ± 0.14). Conclusion: Higher pretreatment PLR was associated with BCVA in patients with RVO-ME and its subtypes who were treated with anti-VEGF drugs. The PLR may be used as a predictive and prognostic tool for effective intravitreal injection treatment outcomes.
References
1.
Jonas
JB
, Monés
J
, Glacet-Bernard
A
, Coscas
G
. Retinal Vein Occlusions
. Dev Ophthalmol
. 2017
;58
:139
–67
.
[PubMed]
0250-37512.
Rogers
S
, McIntosh
RL
, Cheung
N
, Lim
L
, Wang
JJ
, Mitchell
P
, et al.; International Eye Disease Consortium
. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia
. Ophthalmology
. 2010
Feb
;117
(2
):313
–9.e1
.
[PubMed]
0161-64203.
Zhao
F
, Du
F
, Shi
D
, Zhou
W
, Jiang
Y
, Ma
L
. Mapping research trends of retinal vein occlusion from 2009 to 2018: a bibliometric analysis
. PeerJ
. 2019
Aug
;7
:e7603
.
[PubMed]
2167-83594.
Babiuch
AS
, Han
M
, Conti
FF
, Wai
K
, Silva
FQ
, Singh
RP
. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion
. JAMA Ophthalmol
. 2019
Jan
;137
(1
):38
–46
.
[PubMed]
2168-61655.
Noma
H
, Mimura
T
, Eguchi
S
. Association of inflammatory factors with macular edema in branch retinal vein occlusion
. JAMA Ophthalmol
. 2013
Feb
;131
(2
):160
–5
.
[PubMed]
2168-61656.
Rezar-Dreindl
S
, Eibenberger
K
, Pollreisz
A
, Bühl
W
, Georgopoulos
M
, Krall
C
, et al. Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion
. Acta Ophthalmol
. 2017
Mar
;95
(2
):e119
–27
.
[PubMed]
1755-375X7.
Vinores
SA
, Derevjanik
NL
, Ozaki
H
, Okamoto
N
, Campochiaro
PA
. Cellular mechanisms of blood-retinal barrier dysfunction in macular edema
. Doc Ophthalmol
. 1999
;97
(3-4
):217
–28
.
[PubMed]
0012-44868.
Noma
H
, Funatsu
H
, Yamasaki
M
, Tsukamoto
H
, Mimura
T
, Sone
T
, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6
. Am J Ophthalmol
. 2005
Aug
;140
(2
):256
–61
.
[PubMed]
0002-93949.
Jiang
Y
, Mieler
WF
. Update on the Use of Anti-VEGF Intravitreal Therapies for Retinal Vein Occlusions
. Asia Pac J Ophthalmol (Phila)
. 2017
Nov-Dec
;6
(6
):546
–53
.
[PubMed]
2162-098910.
Krakowska
M
, Dębska-Szmich
S
, Czyżykowski
R
, Zadrożna-Nowak
A
, Potemski
P
. The prognostic impact of neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio in patients with advanced colorectal cancer treated with first-line chemotherapy
. Prz Gastroenterol
. 2018
;13
(3
):218
–22
.
[PubMed]
1895-577011.
Bakirci
EM
, Topcu
S
, Kalkan
K
, Tanboga
IH
, Borekci
A
, Sevimli
S
, et al. The role of the nonspecific inflammatory markers in determining the anatomic extent of venous thromboembolism
. Clin Appl Thromb Hemost
. 2015
Mar
;21
(2
):181
–5
.
[PubMed]
1076-029612.
Fu
H
, Qin
B
, Hu
Z
, Ma
N
, Yang
M
, Wei
T
, et al. Neutrophil- and platelet-to-lymphocyte ratios are correlated with disease activity in rheumatoid arthritis
. Clin Lab
. 2015
;61
(3-4
):269
–73
.
[PubMed]
1433-651013.
Dursun
A
, Ozturk
S
, Yucel
H
, Ozec
AV
, Dursun
FG
, Toker
MI
, et al. Association of neutrophil/lymphocyte ratio and retinal vein occlusion
. Eur J Ophthalmol
. 2015
Jul-Aug
;25
(4
):343
–6
.
[PubMed]
1120-672114.
Rehak
M
, Wiedemann
P
. Retinal vein thrombosis: pathogenesis and management
. J Thromb Haemost
. 2010
Sep
;8
(9
):1886
–94
.
[PubMed]
1538-793315.
Jaulim
A
, Ahmed
B
, Khanam
T
, Chatziralli
IP
. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature
. Retina
. 2013
May
;33
(5
):901
–10
.
[PubMed]
0275-004X16.
Kesler
A
, Shalev
V
, Rogowski
O
, Shimron
O
, Shainberg
B
, Sela
BA
, et al. Comparative analysis of homocysteine concentrations in patients with retinal vein occlusion versus thrombotic and atherosclerotic disorders
. Blood Coagul Fibrinolysis
. 2008
Jun
;19
(4
):259
–62
.
[PubMed]
0957-523517.
Horne
BD
, Anderson
JL
, John
JM
, Weaver
A
, Bair
TL
, Jensen
KR
, et al.; Intermountain Heart Collaborative Study Group
. Which white blood cell subtypes predict increased cardiovascular risk?
J Am Coll Cardiol
. 2005
May
;45
(10
):1638
–43
.
[PubMed]
0735-109718.
Rodrigues
SF
, Granger
DN
. Blood cells and endothelial barrier function
. Tissue Barriers
. 2015
Apr
;3
(1-2
):e978720
.
[PubMed]
2168-836219.
Bian
C
, Wu
Y
, Shi
Y
, Xu
G
, Wang
J
, Xiang
M
, et al. Predictive value of the relative lymphocyte count in coronary heart disease
. Heart Vessels
. 2010
Nov
;25
(6
):469
–73
.
[PubMed]
0910-832720.
González-Fajardo
JA
, Brizuela-Sanz
JA
, Aguirre-Gervás
B
, Merino-Díaz
B
, Del Río-Solá
L
, Martín-Pedrosa
M
, et al. Prognostic significance of an elevated neutrophil-lymphocyte ratio in the amputation-free survival of patients with chronic critical limb ischemia
. Ann Vasc Surg
. 2014
May
;28
(4
):999
–1004
.
[PubMed]
0890-509621.
Bagley
SJ
, Kothari
S
, Aggarwal
C
, Bauml
JM
, Alley
EW
, Evans
TL
, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
. Lung Cancer
. 2017
Apr
;106
:1
–7
.
[PubMed]
0169-500222.
Lattanzi
S
, Cagnetti
C
, Provinciali
L
, Silvestrini
M
. Neutrophil-to-Lymphocyte Ratio Predicts the Outcome of Acute Intracerebral Hemorrhage
. Stroke
. 2016
Jun
;47
(6
):1654
–7
.
[PubMed]
0039-249923.
Turkseven Kumral
E
, Yenerel
NM
, Ercalik
NY
, Imamoglu
S
, Vural
ET
. Neutrophil/lymphocyte ratio and mean platelet volume in branch retinal vein occlusion
. Saudi J Ophthalmol
. 2016
Apr-Jun
;30
(2
):105
–8
.
[PubMed]
1319-453424.
Ding
D
, Liu
X
, Duan
J
, Guo
SW
. Platelets are an unindicted culprit in the development of endometriosis: clinical and experimental evidence
. Hum Reprod
. 2015
Apr
;30
(4
):812
–32
.
[PubMed]
0268-116125.
Franco
AT
, Corken
A
, Ware
J
. Platelets at the interface of thrombosis, inflammation, and cancer
. Blood
. 2015
Jul
;126
(5
):582
–8
.
[PubMed]
0006-497126.
Xu
XR
, Zhang
D
, Oswald
BE
, Carrim
N
, Wang
X
, Hou
Y
, et al. Platelets are versatile cells: new discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond
. Crit Rev Clin Lab Sci
. 2016
Dec
;53
(6
):409
–30
.
[PubMed]
1040-836327.
Vinholt
PJ
, Hvas
AM
, Frederiksen
H
, Bathum
L
, Jørgensen
MK
, Nybo
M
. Platelet count is associated with cardiovascular disease, cancer and mortality: A population-based cohort study
. Thromb Res
. 2016
Dec
;148
:136
–42
.
[PubMed]
0049-384828.
Bailon-Cuadrado
M
, Choolani-Bhojwani
E
, Tejero-Pintor
FJ
, Sanchez-Gonzalez
J
, Rodriguez-Lopez
M
, Perez-Saborido
B
, et al. Preoperative platelet-lymphocyte ratio is an independent factor of poor prognosis after curative surgery for colon cancer
. Updates Surg
. 2018
Mar
;70
(1
):33
–9
.
[PubMed]
2038-131X29.
Seropian
IM
, Romeo
FJ
, Pizarro
R
, Vulcano
NO
, Posatini
RA
, Marenchino
RG
, et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as predictors of survival after heart transplantation
. ESC Heart Fail
. 2018
Feb
;5
(1
):149
–56
.
[PubMed]
2055-582230.
Janssen
MC
, den Heijer
M
, Cruysberg
JR
, Wollersheim
H
, Bredie
SJ
. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors
. Thromb Haemost
. 2005
Jun
;93
(6
):1021
–6
.
[PubMed]
0340-624531.
El
FL
, Khaldi
N
, Hmaied
W
, Ksantini
I
, Mestiri
A
, Doggi
M
. Rev Med Interne
. 2007
;28
(11
):742
–5
.
[PubMed]
0248-866332.
Serfőző
G
, Horváth
T
, Földesi
I
, Rafael
B
, von Känel
R
, Keresztes
M
. The Monocyte-to-Lymphocyte Ratio Correlates with Psycho-Neuro-Inflammatory Factors in Patients with Stable Coronary Artery Disease
. Neuroimmunomodulation
. 2016
;23
(2
):67
–74
.
[PubMed]
1021-740133.
Hu
YX
, Xu
XX
, Shao
Y
, Yuan
GL
, Mei
F
, Zhou
Q
, et al. The prognostic value of lymphocyte-to-monocyte ratio in retinopathy of prematurity
. Int J Ophthalmol
. 2017
Nov
;10
(11
):1716
–21
.
[PubMed]
2222-395934.
Avery
RL
, Castellarin
AA
, Steinle
NC
, Dhoot
DS
, Pieramici
DJ
, See
R
, et al. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
. Retina
. 2017
Oct
;37
(10
):1847
–58
.
[PubMed]
0275-004X35.
Zhang
M
, Yu
D
, Yang
C
, Xia
Q
, Li
W
, Liu
B
, et al. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization
. Pharm Res
. 2009
Jan
;26
(1
):204
–10
.
[PubMed]
0724-874136.
Li
F
, Sun
M
, Guo
J
, Ma
A
, Zhao
B
. Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion
. Curr Eye Res
. 2017
Aug
;42
(8
):1174
–8
.
[PubMed]
0271-3683© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
